Carla Valsecchi

Carla Valsecchi

Auto-generated profile, based on publicly available information

Carla Valsecchi

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2019 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CVCarla Valsecchi
Carla Valsecchi
MMMaribel Mirabet
Maribel Mirabet
Ilaria ManciniIlaria Mancini
Ilaria Mancini
MBMarina Biganzoli
Marina Biganzoli
LSLucia Schiavone
Lucia Schiavone
FPFlora Peyvandi
Flora Peyvandi
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) characterized by the severe deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (< 10%). Rapid ADAMTS13 testing is crucial for an early diagnosis and optimal management of acute TTP. We evaluated the performance of the HemosIL AcuStar ADAMTS13 activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States), a fully automated chemiluminescent immunoassay with an analytical time of 33 minutes. A method comparison study was performed on 176 samples from 49 healthy donors and 127 TMA patients (109 TTP, 7 atypical hemolytic uremic syndrome, 11 other TMAs), comparing this new assay with an in-house FRETS-VWF73 assay and a commercial enzyme-linked immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Activity, Technoclone GmbH, Vienna, Austria). Agreement between methods was assessed with focus on ADAMTS13 activity less than 10%, the medical decision level relevant for TTP diagnosis. The HemosIL AcuStar ADAMTS13 Activity showed good correlation with both the FRETS-VWF73 (r = 0.96) and ELISA (r = 0.96) methods. Slope of the Passing–Bablok regression was 1.05 for FRETS-VWF73 and 1.02 for ELISA, and absolute bias at the medical decision level was +0.1 and +0.3%, respectively. The study also revealed high agreement with FRETS-VWF73 (kappa 0.97) and ELISA (kappa 0.98) methods in classifying TTP patients with a severe deficiency of ADAMTS13 activity. Because of its short turnaround time and full automation, the HemosIL AcuStar ADAMTS13 activity assay might become the assay of choice to rapidly test ADAMTS13 activity in plasma and thus establish the diagnosis of acute TTP in emergency settings.

28 December 2020 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
CVCarla Valsecchi
Carla Valsecchi
MGMarco Gobbi
Marco Gobbi
MBMarten Beeg
Marten Beeg
TATy Adams
Ty Adams
GCGiancarlo Castaman
Giancarlo Castaman
FPFlora Peyvandi
Flora Peyvandi

1 January 2011 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
CVCarla Valsecchi
Carla Valsecchi
MBMariateresa Bajetta
Mariateresa Bajetta
MSMarta Spreafico
Marta Spreafico
RCRaimondo De Cristofaro
Raimondo De Cristofaro
FPFlora Peyvandi
Flora Peyvandi
RPRoberta Palla
Roberta Palla

3 June 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
SASara Arcudi
Sara Arcudi
Roberta GualtierottiRoberta Gualtierotti
Roberta Gualtierotti
ESErica Scalambrino
Erica Scalambrino
MCMarigrazia Clerici
Marigrazia Clerici
SHShermarke Hassan
Shermarke Hassan
FPFlora Peyvandi
Flora Peyvandi
Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, some patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at a higher risk of spontaneous joint bleeding. This study aimed to evaluate whether laboratory measurements (global coagulation assays and emicizumab concentration) and/or arthropathy scores can distinguish patients at higher risk of spontaneous joint bleeding while on emicizumab prophylaxis. A thrombin generation assay was performed upon the addition of tissue factor and synthetic phospholipids. Nonactivated thromboelastography was performed on citrated whole blood. Emicizumab concentrations were measured using a modified 1-stage factor VIII assay. The degree of hemophilic arthropathy was assessed using the Hemophilia Joint Health Score and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. A Cox proportional hazards model was used to evaluate the association between variables and bleeding. The predictive power of these variables was investigated using receiver operating characteristic (ROC) analysis. Forty patients with severe HA, with or without inhibitors, on emicizumab prophylaxis were enrolled in an observational cohort study. Ten of 40 developed spontaneous joint bleeding. None of the laboratory parameters were able to distinguish patients with a higher risk of spontaneous joint bleeding. ROC analysis showed that during emicizumab prophylaxis, only the presence of synovitis and a higher HEAD-US score were associated with spontaneous joint bleeding (area under the curve, 0.84). A greater degree of arthropathy and the presence of synovitis could help predict the risk of spontaneous joint bleeding in patients with HA on emicizumab prophylaxis.

4 November 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
CVCarla Valsecchi
Carla Valsecchi
Roberta GualtierottiRoberta Gualtierotti
Roberta Gualtierotti
SASara Arcudi
Sara Arcudi
ACAlessandro Ciavarella
Alessandro Ciavarella
LSLucia Schiavone
Lucia Schiavone
FPFlora Peyvandi
Flora Peyvandi

14 December 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
FPFlora Peyvandi
Flora Peyvandi
SMSyna Miri
Syna Miri
PBPaolo Bucciarelli
Paolo Bucciarelli
CVCarla Valsecchi
Carla Valsecchi
LSLucia Schiavone
Lucia Schiavone
TGthe SIPPET group
the SIPPET group